Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Readers help support Windows Report. We may get a commission if you buy through our links. Whenever you encounter an error in Windows, it certainly is a cause for ...

Ever wished your training or events had more personal spark? Phil Walsh shares his approach to making any experience more connected When we began planning a forum, we ...

The AI automatically generates outlines, text, and visual elements, saving significant time and effort. The platform provides a variety of customizable templates suitable for diverse needs such as ...